Status:
RECRUITING
Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA)
Lead Sponsor:
Instituto Valenciano de Infertilidad, IVI VALENCIA
Conditions:
Infertility, Female
Reproductive Sterility
Eligibility:
FEMALE
18-35 years
Phase:
NA
Brief Summary
IVF patients frequently experience physical, emotional or physicological burden; this is particularly relevant in the case of oocyte donors, since young women undergo a procedure that is of no health ...
Eligibility Criteria
Inclusion
- Signature of the subject's informed consent prior to any trial-related activity.
- Age between 18 and 35 years (both inclusive).
- Regular menstrual cycle, from 25 to 35 days (both inclusive).
- Absence of physical and psychological illness at the time of donation at the discretion of the investigator.
- BMI 18-28 kg/m2 (both inclusive) at the time of donation.
- No personal or family history of interest at the discretion of the investigator.
- Normal uterus and ovaries, without organic pathology.
- No polycystic ovaries.
- Antral follicle count greater than 12 in the sum of the two ovaries at the time of the screening visit.
- Normal karyotype.
- Negative infectious disease screening (Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus and Syphilis).
- General analysis with hemogram, hemostasis and biochemistry with parameters within normality.
Exclusion
- Concurrent participation in another clinical trial.
- Previous participation in this clinical trial.
- Use of long-term hormonal contraception (hormonal IUD or subcutaneous implants) at least 1 month prior to enrollment.
- Any systemic or metabolic disorder (i.e.: diabetes...) that contraindicates the use of gonadotropins.
- Personal history of thrombophlebitis and thromboembolic phenomena and hypertension.
- Severe hepatic insufficiency, cardiovascular disease
- Suspicion or evidence of breast malignancy or hormone-dependent genital organs.
- Known hypersensitivity to AMP or its excipients
- Any reason for exclusion from the oocyte donation program.
Key Trial Info
Start Date :
July 8 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
318 Patients enrolled
Trial Details
Trial ID
NCT06193135
Start Date
July 8 2025
End Date
December 31 2025
Last Update
September 15 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
IVI Valencia
Valencia, Valencia, Spain, 46015
2
Ivi Valencia
Valencia, Valencia, Spain, 46015